Different luminance- and texture-defined contrast sensitivity profiles for school-aged children.

Funder: Fonds de Recherche du Québec - Santé; doi: http://dx.doi.org/10.13039/501100000156Funder: Canadian Institutes of Health Research; doi: http://dx.doi.org/10.13039/501100000024Our current understanding of how the visual brain develops is based largely on the study of luminance-defined information processing. This approach, however, is somewhat limiting, since everyday scenes are composed of complex images, consisting of information characterized by physical attributes relating to both luminance and texture. Few studies have explored how contrast sensitivity to texture-defined information develops, particularly throughout the school-aged years. The current study investigated how contrast sensitivity to luminance- (luminance-modulated noise) and texture-defined (contrast-modulated noise) static gratings develops in school-aged children. Contrast sensitivity functions identified distinct profiles for luminance- and texture-defined gratings across spatial frequencies (SFs) and age. Sensitivity to luminance-defined gratings reached maturity in childhood by the ages of 9-10 years for all SFs (0.5, 1, 2, 4 and 8 cycles/degree or cpd). Sensitivity to texture-defined gratings reached maturity at 5-6 years for low SFs and 7-8 years for high SFs (i.e., 4 cpd). These results establish that the processing of luminance- and texture-defined information develop differently as a function of SF and age

Flow Duration Curve from Satellite:Potential of a Lifetime SWOT Mission

A flow duration curve (FDC) provides a comprehensive description of the hydrological regime of a catchment and its knowledge is fundamental for many water-related applications (e.g., water management and supply, human and irrigation purposes, etc.). However, relying on historical streamflow records, FDCs are constrained to gauged stations and, thus, typically available for a small portion of the world’s rivers. The upcoming Surface Water and Ocean Topography satellite (SWOT; in orbit from 2021) will monitor, worldwide, all rivers larger than 100 m in width (with a goal to observe rivers as small as 50 m) for a period of at least three years, representing a potential groundbreaking source of hydrological data, especially in remote areas. This study refers to the 130 km stretch of the Po River (Northern Italy) to investigate SWOT potential in providing discharge estimation for the construction of FDCs. In particular, this work considers the mission lifetime (three years) and the three satellite orbits (i.e., 211, 489, 560) that will monitor the Po River. The aim is to test the ability to observe the river hydrological regime, which is, for this test case, synthetically reproduced by means of a quasi-2D hydraulic model. We consider different river segmentation lengths for discharge estimation and we build the FDCs at four gauging stations placed along the study area referring to available satellite overpasses (nearly 52 revisits within the mission lifetime). Discharge assessment is performed using the Manning equation, under the assumption of a trapezoidal section, known bathymetry, and roughness coefficient. SWOT observables (i.e., water level, water extent, etc.) are estimated by corrupting the values simulated with the quasi-2D model according to the mission requirements. Remotely-sensed FDCs are compared with those obtained with extended (e.g., 20–70 years) gauge datasets. Results highlight the potential of the mission to provide a realistic reconstruction of the flow regimes at different locations. Higher errors are obtained at the FDC tails, where very low or high flows have lower likelihood of being observed, or might not occur during the mission lifetime period. Among the tested discretizations, 20 km stretches provided the best performances, with root mean absolute errors, on average, lower than 13.3%

New Mediterranean Biodiversity Records (December 2019)

This paper is a collection of novel distributional records of 20 species belonging to 8 phyla (Chlorophyta, Rhodophyta, Cnidaria, Ctenophora, Annelida, Mollusca, Arthropoda and Chordata) from 11 Mediterranean countries, namely, Spain: an additional record of the Canary dentex Dentex canariensis is reported from Spain (Valencia), this is the northernmost record of this species in the Mediterranean; Algeria: the first documented record of Caulerpa chemnitzia is reported from the Algerian coast; France: the first record of the Spotted sea hare Aplysia dactylomela is reported from the eastern coast of Corsica; Italy: the first records of the Lessepsian polychaete Dorvillea similis and the alien bivalve Isognomon legumen are reported from Italian waters while additional records of Mnemiopsis leidyi in the south Adriatic are provided;  Libya: the first record of an alien mollusc Crepidula fornicata is reported from Libyan waters; Malta: multiple sightings of gelatinous species Apolemia uvaria, Phacellophora camtschatica and Physophora hydrostatica are reported for the first time from Maltese waters, as well as the first tentative record of the Orange-spotted grouper Epinephelus cfr. coioides; Greece: an occurrence of a rare Bigeye thresher shark Alopias superciliosus is reported from Hellenic Ionian waters, while the first records of the alien Mertens’ prawn-goby Vanderhorstia mertensi, the recently described cyclopoid copepod Oithona davisae and the alien red seaweed Asparagopsis armata are reported from the Aegean Sea. The presence of the micromollusc Euthymella colzumensis is confirmed for Greece; Cyprus: the first record of the red cornetfish Fistularia petimba is reported from Cyprus; Turkey: the first record of the alien jellyfish Marivagia stellata is reported from south-eastern Turkey; Israel: the first records of the sea nettle Chrysaora sp. in the Levant are reported

Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.

BACKGROUND: Staphylococcus aureus bacteraemia is a common and frequently fatal infection. Adjunctive rifampicin may enhance early S. aureus killing, sterilise infected foci and blood faster, and thereby reduce the risk of dissemination, metastatic infection and death. OBJECTIVES: To determine whether or not adjunctive rifampicin reduces bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. Secondary objectives included evaluating the impact of rifampicin on all-cause mortality, clinically defined failure/recurrence or death, toxicity, resistance emergence, and duration of bacteraemia; and assessing the cost-effectiveness of rifampicin. DESIGN: Parallel-group, randomised (1 : 1), blinded, placebo-controlled multicentre trial. SETTING: UK NHS trust hospitals. PARTICIPANTS: Adult inpatients (≥ 18 years) with meticillin-resistant or susceptible S. aureus grown from one or more blood cultures, who had received < 96 hours of antibiotic therapy for the current infection, and without contraindications to rifampicin. INTERVENTIONS: Adjunctive rifampicin (600-900 mg/day, oral or intravenous) or placebo for 14 days in addition to standard antibiotic therapy. Investigators and patients were blinded to trial treatment. Follow-up was for 12 weeks (assessments at 3, 7, 10 and 14 days, weekly until discharge and final assessment at 12 weeks post randomisation). MAIN OUTCOME MEASURES: The primary outcome was all-cause bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. RESULTS: Between December 2012 and October 2016, 758 eligible participants from 29 UK hospitals were randomised: 370 to rifampicin and 388 to placebo. The median age was 65 years [interquartile range (IQR) 50-76 years]. A total of 485 (64.0%) infections were community acquired and 132 (17.4%) were nosocomial; 47 (6.2%) were caused by meticillin-resistant S. aureus. A total of 301 (39.7%) participants had an initial deep infection focus. Standard antibiotics were given for a median of 29 days (IQR 18-45 days) and 619 (81.7%) participants received flucloxacillin. By 12 weeks, 62 out of 370 (16.8%) patients taking rifampicin versus 71 out of 388 (18.3%) participants taking the placebo experienced bacteriological (microbiologically confirmed) failure/recurrence or died [absolute risk difference -1.4%, 95% confidence interval (CI) -7.0% to 4.3%; hazard ratio 0.96, 95% CI 0.68 to 1.35; p = 0.81]. There were 4 (1.1%) and 5 (1.3%) bacteriological failures (p = 0.82) in the rifampicin and placebo groups, respectively. There were 3 (0.8%) versus 16 (4.1%) bacteriological recurrences (p = 0.01), and 55 (14.9%) versus 50 (12.9%) deaths without bacteriological failure/recurrence (p = 0.30) in the rifampicin and placebo groups, respectively. Over 12 weeks, there was no evidence of differences in clinically defined failure/recurrence/death (p = 0.84), all-cause mortality (p = 0.60), serious (p = 0.17) or grade 3/4 (p = 0.36) adverse events (AEs). However, 63 (17.0%) participants in the rifampicin group versus 39 (10.1%) participants in the placebo group experienced antibiotic or trial drug-modifying AEs (p = 0.004), and 24 (6.5%) participants in the rifampicin group versus 6 (1.5%) participants in the placebo group experienced drug-interactions (p = 0.0005). Evaluation of the costs and health-related quality-of-life impacts revealed that an episode of S. aureus bacteraemia costs an average of £12,197 over 12 weeks. Rifampicin was estimated to save 10% of episode costs (p = 0.14). After adjustment, the effect of rifampicin on total quality-adjusted life-years (QALYs) was positive (0.004 QALYs), but not statistically significant (standard error 0.004 QALYs). CONCLUSIONS: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S. aureus bacteraemia. FUTURE WORK: Given the substantial mortality, other antibiotic combinations or improved source management should be investigated. TRIAL REGISTRATIONS: Current Controlled Trials ISRCTN37666216, EudraCT 2012-000344-10 and Clinical Trials Authorisation 00316/0243/001. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 59. See the NIHR Journals Library website for further project information.NIHR HTA Programm

Strategy for the management of diabetic macular edema: the European Vitreo-Retinal Society macular edema study

Objective. To compare the efficacy of different therapies in the treatment of diabetic macular edema (DME). Design. Nonrandomized, multicenter clinical study. Participants. 86 retina specialists from 29 countries provided clinical information on 2,603 patients with macular edema including 870 patients with DME. Methods. Reported data included the type and number of treatment(s) performed, the pre-and posttreatment visual acuities, and other clinical findings.The results were analyzed by the French INSEE (National Institute of Statistics and Economic Studies). Main Outcome Measures. Mean change of visual acuity and mean number of treatments performed. Results.The change in visual acuity over time in response to each treatment was plotted in second order polynomial regression trend lines. Intravitreal triamcinolone monotherapy resulted in some improvement in vision. Treatmentwith threshold or subthreshold grid laser also resulted in minimal vision gain. Anti-VEGF therapy resulted in more significant visual improvement. Treatment with pars plana vitrectomy and internal limiting membrane (ILM) peeling alone resulted in an improvement in vision greater than that observed with anti-VEGF injection alone. In our DME study, treatment with vitrectomy and ILM peeling alone resulted in the better visual improvement compared to other therapies